The progressive reduction in the pulsatile secretion of Growth Hormone (GH) from the anterior pituitary gland that occurs naturally with advancing chronological age. This physiological change, often termed somatopause, results in lower circulating levels of Insulin-like Growth Factor 1 (IGF-1), impacting numerous metabolic and somatic functions. Clinically, this decline contributes to shifts in body composition, including reduced lean body mass and increased visceral adiposity, representing a fundamental aspect of hormonal aging.
Origin
This phenomenon is rooted in endocrinology and human physiology, specifically concerning the hypothalamic-pituitary-somatotropic axis. The term itself is a descriptive clinical phrase combining the biological process of aging with the measurable decrease in somatotropin (GH) output. It highlights a natural, albeit impactful, alteration in the endocrine system’s regulatory capacity over the lifespan.
Mechanism
The primary mechanism involves altered hypothalamic regulation, particularly an increase in Somatostatin (GH-inhibiting hormone) tone and a decrease in Growth Hormone-Releasing Hormone (GHRH) pulsatility. Additionally, the pituitary somatotrophs may exhibit reduced sensitivity to GHRH stimulation and a lower secretory capacity over time. This altered neuroendocrine signaling diminishes the amplitude and frequency of nocturnal GH pulses, which are critical for tissue repair and metabolic homeostasis.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.